Lynparza (olaparib) is the first PARP inhibitor approved to treat breast cancer, and the first medicine ever for metastatic breast cancer who have a “BRCA” gene mutation.

A new study found that cabozantinib (Cabometyx) was more effective than everolimus in advanced renal cell carcinoma and bone metastases.

Pembrolizumab showed positive results in heavily pretreated, PD-L1–positive advanced esophageal carcinoma.

Specific strains of intestinal bacteria can improve the response rate to immunotherapy for patients being treated for advanced melanoma.

Eight important updates in lung cancer.

Darzalex (daratumumab) combination under review as first-line option.

Immunotherapy nivolumab has been linked to HIV reservoir decrease in a lung cancer patient. 

In a pilot study immunotherapy proved active in some patients with metastatic, trastuzumab (Herceptin)-resistant HER2-positive breast cancer.

Researchers are suggesting that metastatic tumours in the lung can be successfully eradicated using cryotherapy – literally turning the masses into ice balls that are then resorbed by the body.

Mavenclad (cladribine) has become the multiple sclerosis therapy of choice for 1 in 5 neurologists in Germany and the UK. Meanwhile, many European neurologists wait for Ocrevus (ocrelizumab).

With recent drops in new HIV diagnoses being linked to buying PrEP through online buyers clubs, the addition of PrEP to the WHO's essential medicine list, and the recent approval of generic PrEP in the US - here’s what you need to know.

PTC Therapeutics announce the launch of Emflaza for the treatment of Duchenne muscular dystrophy (DMD) within the coming weeks, with an expected net price of $35,000.

On Sunday former US president and Nobel Peace Prize laureate proclaimed to a Sunday school class that he is cancer-free.

Impressive results have been published last week regarding two new immunotherapies.